Organic Anion-Transporting Polypeptides

Drug Transporters: Molecular Characterization and Role in Drug Disposition

Volumn , Issue , 2006, Pages 75-104

  Tirona, Rommel G ^a   Kim, Richard B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

OATP substrates and inhibitors; OATPs expression and regulation; Organic anion transporting polypeptides

Indexed keywords

EID: 79960743229     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470140505.ch5     Document Type: Chapter

References (161)

1. Hagenbuch B, Meier PJ. 2003. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609(1): 1-18.
2. Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447(5): 653-665.
3. Meier-Abt F, Mokrab Y, Mizuguchi K. 2005. Organic anion transporting polypeptides of the OATP/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode. J Membr Biol 208(3): 213-227.
4. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ. 1994. Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 91(1): 133-137.
5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6(1): 1-42.
6. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. 2005. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 102(6): 2063-2068.
7. Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM. 2005. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A 102(6): 2198-2203.
8. Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW. 2000. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 10(1): 91-93.
9. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. 2002. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 16(10): 2283-2296.
10. Saito H, Masuda S, Inui K. 1996. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem 271(34): 20719-20725.
11. Masuda S, Ibaramoto K, Takeuchi A, Saito H, Hashimoto Y, Inui KI. 1999. Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney. Mol Pharmacol 55(4): 743-752.
12. Hanggi E, Freimoser Grundschober A, Leuthold S, Meier PJ, St-Pierre MV. 2006. Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, Oatp2b1. Mol Pharmacol 70(3): 806-817.
13. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. 2005. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280(10): 9610-9617.
14. Wang P, Wang JJ, Xiao Y, Murray JW, Novikoff PM, Angeletti RH, Orr GA, Lan D, Silver DL, Wolkoff AW. 2005. Interaction with PDZK1 is required for expression of organic anion transporting protein 1A1 on the hepatocyte surface. J Biol Chem 280(34): 30143-30149.
15. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, Meier PJ. 1995. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109(4): 1274-1282.
16. Konig J, Cui Y, Nies AT, Keppler D. 2000. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278(1): G156-G164.
17. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. 2004. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308(2): 438-445.
18. 3-exchange. J Biol Chem 272(42): 26340-26345.
19. Li L, Lee TK, Meier PJ, Ballatori N. 1998. Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem 273(26): 16184-16191.
20. Li L, Meier PJ, Ballatori N. 2000. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 58(2): 335-340.
21. Mittur A, Wolkoff AW, Kaplowitz N. 2002. The thiol sensitivity of glutathione transport in sidedness-sorted basolateral liver plasma membrane and in Oatp1-expressing HeLa cell membrane. Mol Pharmacol 61(2): 425-435.
22. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. 2003. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306(2): 703-708.
23. Marin JJ, Mangas D, Martinez-Diez MC, El-Mir MY, Briz O, Serrano MA. 2003. Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH. Biochim Biophys Acta 1611(1-2): 249-257.
24. Briz O, Romero MR, Martinez-Becerra P, Macias RI, Perez MJ, Jimenez F, San Martin FG, Marin JJ. 2006. Oatp8/1B3-mediated cotransport of bile acids and glutathione: An export pathway for organic anions from hepatocytes? J Biol Chem 281(41): 30326-30335.
25. Chan BS, Endo S, Kanai N, Schuster VL. 2002. Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT. Am J Physiol Renal Physiol 282(6): F1097-F1102.
26. Konig J, Cui Y, Nies AT, Keppler D. 2000. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275(30): 23161-23168.
27. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. 2001. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120(2): 525-533.
28. Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. 2005. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65(24): 11419-11428.
29. St-Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. 2002. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 87(4): 1856-1863.
30. Gao B, Huber RD, Wenzel A, Vavricka SR, Ismair MG, Reme C, Meier PJ. 2005. Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exp Eye Res 80(1): 61-72.
31. Schiffer R, Neis M, Holler D, Rodriguez F, Geier A, Gartung C, Lammert F, Dreuw A, Zwadlo-Klarwasser G, Merk H, Jugert F, Baron JM. 2003. Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J Invest Dermatol 120(2): 285-291.
32. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, St-Pierre MV. 2003. Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 88(8): 3902-3912.
33. Campbell CG, Spray DC, Wolkoff AW. 1993. Extracellular ATP4-modulates organic anion transport by rat hepatocytes. J Biol Chem 268(21): 15399-15404.
34. Glavy JS, Wu SM, Wang PJ, Orr GA, Wolkoff AW. 2000. Down-regulation by extracellular ATP of rat hepatocyte organic anion transport is mediated by serine phosphorylation of oatp1. J Biol Chem 275(2): 1479-1484.
35. Guo GL, Klaassen CD. 2001. Protein kinase C suppresses rat organic anion transporting polypeptide 1-and 2-mediated uptake. J Pharmacol Exp Ther 299(2): 551-557.
36. Xiao Y, Nieves E, Angeletti RH, Orr GA, Wolkoff AW. 2006. Rat organic anion transporting protein 1A1 (Oatp1a1): purification and phosphopeptide assignment. Biochemistry 45(10): 3357-3369.
37. Lee TK, Koh AS, Cui Z, Pierce RH, Ballatori N. 2003. N-Glycosylation controls functional activity of Oatp1, an organic anion transporter. Am J Physiol Gastrointest Liver Physiol 285(2): G371-G381.
38. Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 276(38): 35669-35675.
39. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6): 1793-1806.
40. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B, Stieger B, Meier PJ, Beuers U, Kramer W, et al. 1997. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 113(4): 1295-1305.
41. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294(1): 73-79.
42. Hanggi E, Grundschober AF, Leuthold S, Meier PJ, St-Pierre MV. 2006. Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, OATP2B1. Mol Pharmacol 70(3): 806-817.
43. Sugiura T, Kato Y, Tsuji A. 2006. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. J Control Release 116(2): 238-246.
44. Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A. 2004. Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm Res 21(10): 1886-1894.
45. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. 1996. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84(4): 575-585.
46. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M. 2001. Hepatocyte nuclear factor-1alphais an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 27(4): 375-382.
47. Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD. 2006. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem Pharmacol 72(4): 512-522.
48. Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA. 2001. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J Biol Chem 276(40): 37206-37214.
49. Li N, Klaassen CD. 2004. Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatplb2; slc21a10) by lipopolysaccharide. Mol Pharmacol 66(3): 694-701.
50. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. 1999. Bile acids: natural ligands for an orphan nuclear receptor. Science 284(5418): 1365-1368.
51. Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA. 2002. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122(7): 1954-1966.
52. Vavricka SR, Jung D, Fried M, Grutzner U, Meier PJ, Kullak-Ublick GA. 2004. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 40(2): 212-218.
53. Ohtsuka H, Abe T, Onogawa T, Kondo N, Sato T, Oshio H, Mizutamari H, Mikkaichi T, Oikawa M, Rikiyama T, et al. 2006. Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specific organic anion transporter-2 gene. J Gastroenterol 41(4): 369-377.
54. Wood M, Ananthanarayanan M, Jones B, Wooton-Kee R, Hoffman T, Suchy FJ, Vore M. 2005. Hormonal regulation of hepatic organic anion transporting polypeptides. Mol Pharmacol 68(1): 218-225.
55. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, et al. 2001. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120(7): 1689-1699.
56. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102(5): 1016-1023.
57. Tirona RG, Kim RB. 2005. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94(6): 1169-1186.
58. Guo GL, Staudinger J, Ogura K, Klaassen CD. 2002. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol Pharmacol 61(4): 832-839.
59. Guo GL, Choudhuri S, Klaassen CD. 2002. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. J Pharmacol Exp Ther 300(1): 206-212.
60. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. 2006. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34(10): 1756-1763.
61. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H. 2006. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66(1): 535-542.
62. Yarim M, Moro S, Huber R, Meier PJ, Kaseda C, Kashima T, Hagenbuch B, Folkers G. 2005. Application of QSAR analysis to organic anion transporting polypeptide 1a5 (Oatp1a5) substrates. Bioorg Med Chem 13(2): 463-471.
63. Chang C, Pang KS, Swaan PW, Ekins S. 2005. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 314(2): 533-541.
64. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A. 2003. Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [{eng}-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol 55(7): 1013-1020.
65. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. 2006. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34: 1109-1115.
66. Tirona RG, Leake BF, Wolkoff AW, Kim RB. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304(1): 223-228.
67. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2006. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34(7): 1229-1236.
68. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. 2002. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302(2): 804-813.
69. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73(6): 554-565.
70. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. 2004. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75(5): 415-421.
71. Niemi M, Schaffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, et al. 2004. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14(7): 429-440.
72. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schenck D. 2005. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the same environment. Clin Pharmacol Ther 78(4): 330-341.
73. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. 2005. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1* 5, SLCO1B1* 15 and SLCO1B1* 15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genom 15(7): 513-522.
74. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. 2005. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33(3): 434-439.
75. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. 2006. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79(5): 427-439.
76. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. 2005. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78(4): 342-350.
77. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. 2005. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78(4): 330-341.
78. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. 2005. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77(6): 468-478.
79. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, Tan ZR, Zhang WX, Yu BN, Wang D, Hu DL, Zhou HH. 2006. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 62(5): 567-572.
80. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. 2005. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59(5): 602-604.
81. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, et al. 2006. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 79(3): 186-196.
82. Xiang X, Rao Jada S, Hua Li H, Fan L, San Tham L, Ing Wong C, Chin Lee S, Lim R, Yu Zhou Q, Cher Goh B, Huat Tan E, Chowbay B. 2006. Pharmacogenetics of SLCO1B1 gene and the impact of * 1b and * 15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genom 16(9): 683-691.
83. Oswald S, Scheuch E, Cascorbi I, Siegmund W. 2006. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Anal Technol Biomed Life Sci 830(1): 143-150.
84. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivisto KT, Neuvonen PJ, Niemi M. 2006. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 61(6): 706-715.
85. Thompson PD, Clarkson P, Karas RH. 2003. Statin-associated myopathy. JAMA 289 (13): 1681-1690.
86. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. 2004. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 19(6): 453-455.
87. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstol K. 2006. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 79(6): 532-539.
88. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T. 2004. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19(5): 375-380.
89. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT. 2006. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79(5): 419-426.
90. Gerloff T, Schaefer M, Mwinyi J, Johne A, Sudhop T, Lutjohann D, Roots I, von Bergmann K. 2006. Influence of the SLCO1B1* 1b and * 5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch Pharmacol 373(1): 45-50.
91. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. 2006. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318(2): 521-529.
92. Letschert K, Keppler D, Konig J. 2004. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14(7): 441-452.
93. Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y. 2006. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab Pharmacokinet 21(2): 165-169.
94. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. 2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71(1): 11-20.
95. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76(2): 167-177.
96. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. 2001. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276(13): 9626-9630.
97. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. 2003. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371(Pt 3): 897-905.
98. Acocella G, Nicolis FB, Tenconi LT. 1965. The effect of an intravenous infusion of rifamycin SV on the excretion of bilirubin, bromsulphalein, and indocyanine green in man. Gastroenterology 49(5): 521-525.
99. Campbell SD, de Morais SM, Xu JJ. 2004. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150(2): 179-187.
100. Wang P, Kim RB, Chowdhury JR, Wolkoff AW. 2003. The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport. J Biol Chem 278(23): 20695-20699.
101. Passamonti S, Terdoslavich M, Margon A, Cocolo A, Medic N, Micali F, Decorti G, Franko M. 2005. Uptake of bilirubin into HepG2 cells assayed by thermal lens spectroscopy. Function of bilitranslocase. FEBS J 272(21): 5522-5535.
102. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. 2004. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 56(5): 682-689.
103. Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K, Sugiyama Y. 2004. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol Res 30(2): 91-95.
104. Huang CS, Huang MJ, Lin MS, Yang SS, Teng HC, Tang KS. 2005. Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet Genom 15(1): 43-50.
105. Gentile S, Persico M, Tiribelli C. 1990. Abnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: the role of reduced affinity of the plasma membrane carrier of organic anions. Hepatology 12(2): 213-217.
106. Suzuki T, Onogawa T, Asano N, Mizutamari H, Mikkaichi T, Tanemoto M, Abe M, Satoh F, Unno M, Nunoki K, et al. 2003. Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol Endocrinol 17(7): 1203-1215.
107. Nomura T, Chang HY, Lu R, Hankin J, Murphy RC, Schuster VL. 2005. Prostaglandin signaling in the renal collecting duct: release, reuptake, and oxidation in the same cell. J Biol Chem 280(31): 28424-28429.
108. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, Ferenci P, Stauber RE, Krejs GJ, Denk H, Zatloukal K, Trauner M. 2001. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33(3): 633-646.
109. Nozawa T, Suzuki M, Takahashi K, Yabuuchi H, Maeda T, Tsuji A, Tamai I. 2004. Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther 311(3): 1032-1037.
110. Nozawa T, Suzuki M, Yabuuchi H, Irokawa M, Tsuji A, Tamai I. 2005. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 22(10): 1634-1641.
111. van den Dobbelsteen DJ, Nobel CS, Schlegel J, Cotgreave IA, Orrenius S, Slater AF. 1996. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 271(26): 15420-15427.
112. Franco R, Cidlowski JA. 2006. SLCO/OATP-like transport of glutathione in FasL-induced apoptosis: Glutathione efflux is coupled to an organic anion exchange and is necessary for the progression of the execution phase of apoptosis. J Biol Chem 281(40): 29542-29557.
113. Ghibelli L, Fanelli C, Rotilio G, Lafavia E, Coppola S, Colussi C, Civitareale P, Ciriolo MR. 1998. Rescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB J 12(6): 479-486.
114. Patel P, Weerasekera N, Hitchins M, Boyd CA, Johnston DG, Williamson C. 2003. Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C, OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta 24(1): 39-44.
115. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274(52): 37161-37168.
116. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273(1): 251-260.
117. Marin JJ, Macias RI, Briz O, Perez MJ, Serrano MA. 2005. Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Ann Hepatol 4(2): 70-76.
118. Lu R, Kanai N, Bao Y, Schuster VL. 1996. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest 98(5): 1142-1149.
119. Schuster VL, Lu R, Coca-Prados M. 1997. The prostaglandin transporter is widely expressed in ocular tissues. Surv Ophthalmol 41 (Suppl 2): S41-S45.
120. Bao Y, Pucci ML, Chan BS, Lu R, Ito S, Schuster VL. 2002. Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 282(6): F1103-F1110.
121. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, et al. 2003. Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol 285(6): F1188-F1197.
122. Sato K, Sugawara J, Sato T, Mizutamari H, Suzuki T, Ito A, Mikkaichi T, Onogawa T, Tanemoto M, Unno M, Abe T, Okamura K. 2003. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta 24(2-3): 144-148.
123. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. 2004. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 101(10): 3569-3574.
124. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27(8): 866-871.
125. Bossuyt X, Muller M, Meier PJ. 1996. Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol 25(5): 733-738.
126. Fujino H, Saito T, Ogawa S, Kojima J. 2005. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 57(10): 1305-1311.
127. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. 2006. Interaction of methotrexate with OATP1A2 and its genetic variants. J Pharmacol Exp Ther 318(2): 521-529.
128. Fischer WJ, Altheimer S, Cattori V, Meier PJ, Dietrich DR, Hagenbuch B. 2005. Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. Toxicol Appl Pharmacol 203(3): 257-263.
129. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311(1): 228-236.
130. Lau YY, Okochi H, Huang Y, Benet LZ. 2006. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316(2): 762-771.
131. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 33(5): 676-682.
132. Fehrenbach T, Cui Y, Faulstich H, Keppler D. 2003. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn-Schmiedebergs Arch Pharmacol 368(5): 415-420.
133. Meier-Abt F, Faulstich H, Hagenbuch B. 2004. Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 1664(1): 64-69.
134. Nozawa T, Sugiura S, Nakajima M, Goto A, Yokoi T, Nezu J, Tsuji A, Tamai I. 2004. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 13(4): 525-253.
135. Lu WJ, Tamai I, Nezu JI, Lai ML, Huang JD. 2006. Organic anion transporting polypeptide-C mediates arsenic uptake in HEK-293 cells. J Biomed Sci 13(4): 525-533.
136. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. 2006. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 34(7): 1247-1254.
137. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T. 2006. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos 34(5): 862-869.
138. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS. 2006. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther 318(1): 395-402.
139. Ismair MG, Stanca C, Ha HR, Renner EL, Meier PJ, Kullak-Ublick GA. 2003. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol Res 26(4): 343-347.
140. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. 2005. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4(8): 815-818.
141. Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, Prueksaritanont T, Lin JH. 2005. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2-and P-glycoprotein-mediated transport. Xenobiotica 35(7): 737-753.
142. Vavricka SR, van Montfoort J, Ha HR, Meier PJ, Fattinger K. 2002. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36(1): 164-172.
143. Wang X, Wolkoff AW, Morris ME. 2005. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33(11): 1666-1672.
144. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. 2005. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33(10): 1477-1481.
145. Maeda K, Kambara M, Tian Y, Hofmann AF, Sugiyama Y. 2006. Uptake of ur-sodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and oatp1B3 (OATP8). Mol Pharmacol 3(1): 70-77.
146. Cui Y, Konig J, Keppler D. 2001. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60(5): 934-943.
147. Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA. 2001. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 121(5): 1185-1190.
148. 2 transport. J Pharmacol Exp Ther 316(3): 1346-1350.
149. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. 2005. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 33(4): 518-523.
150. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. 2006. Predominant Contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34(8): 1423-1431.
151. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. 2006. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34(4): 577-582.
152. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, et al. 2001. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 142(5): 2005-2012.
153. Iida A, Saito S, Sekine A, Mishima C, Kondo K, Kitamura Y, Harigae S, Osawa S, Nakamura Y. 2001. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH: ubiquinone oxidoreductase flavoproteins. J Hum Genet 46(11): 668-683.
154. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. 2004. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14(11): 749-757.
155. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J. 2002. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277(45): 43058-43063.
156. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. 2005. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther 77(4): 291-301.
157. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. 2006. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci 78(24): 2852-2859.
158. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73(6): 538-544.
159. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75(5): 455-463.
160. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J. 1999. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 65(3): 251-261.
161. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72(6): 685-691.